权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Effects of Doxorubicin or OK-432 on Cancer cells during liver regeneration after two-thirds hepatectomy

阿霉素或 OK-432 对三分之二肝切除术后肝再生过程中癌细胞的影响

基本信息

批准号：
03670630
负责人：
MATSUYAMA Takashi
金额：
$ 1.41万
依托单位：
Kyusyu University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1991
资助国家：
日本
起止时间：
1991 至 1993
项目状态：
已结题

项目摘要

Background : Adjuvant chemotherapy may increase the salvage rate after removal of promary liver cancer, but the role of postoperative adjuvant therapy during liver regeneration remains to be clarified.Methods : To evaluate the preventive effects of Doxorubicin or OK-432 for early hepatic recurrence, five groups of WKA rats had viable tumor cell injected directly into the portal vein after two-thirds hepatectomy. Group one was used as a control, the remaining groups had Doxorubicin injected directly into the hepatic artery : immediately, at 24 hours, 48hours, and 72 hours post-operatively. Secondly, four groups of WKA rats underwent two-thirds hepatectomy and similar injection of viable tumor cells. Group A underwent no further treatment. Group B had Doxorubicin injected 24 hours post-operatively. Group C had OK-432 administered into the subcutaneously transpositioned spleen three times prior to two-thirds hepatectomy. Group D underwent the administration of OK-432, and the Doxorubicin injection.Results : When compared with regard to the forms of Doxorubicin administered, there was no statistical difference in survival rates between all groups. There were notable adverse side effects of persistent suppression and delay of liver cell devision after Doxorubicin administration. The mean survival period in Group A, B, C, and D was determined to be 22.6, 20.0, 38.6, and 30.9 days, respectively (p<0.01).Conclusions : Based on the findings we believe adjuvant chemotherapy during the liver regeneration phase is not recommended. OK-432 plays an important role in the preventive effect of liver recurrence after hepatectomy.

工作背景：原发性肝癌切除术后辅助化疗可提高挽救率，但术后辅助治疗在肝再生过程中的作用仍有待澄清。方法：为了评价阿霉素或OK-432对早期肝复发的预防作用，5组WKA大鼠在2/3肝切除术后将活肿瘤细胞直接注入门静脉。第一组作为对照组，其余组直接经肝动脉注射阿霉素：术后即刻、24小时、48小时和72小时。其次，四组WKA大鼠进行了三分之二肝切除术和类似的活肿瘤细胞注射。A组不做进一步处理。B组术后24 h注射阿霉素。C组在三分之二肝切除术前皮下注射OK-432三次。D组接受OK-432和阿霉素注射液的给药。结果：当比较给予阿霉素的形式时，所有组之间的存活率没有统计学差异。阿霉素给药后有明显的持续抑制和肝细胞分裂延迟的不良反应。A、B、C和D组的平均生存期分别为22.6、20.0、38.6和30.9天（p<0.01）。OK-432在肝切除术后肝复发的预防作用中起重要作用。